Effect of Dexamethasone Implant on Optic Disc
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03927118|
Recruitment Status : Completed
First Posted : April 25, 2019
Last Update Posted : May 13, 2019
|Condition or disease||Intervention/treatment|
|Glaucoma and Ocular Hypertension Diabetic Macular Edema Intravenous Drug Usage Optic Disk Disorders||Procedure: intravitreal dexamethasone implant application|
Diabetic macular edema is the most frequent ocular complication of diabetes resulting in irreversible loss of vision if untreated. Dexamethasone implant implant is used to treat macular edema due to diabetes. It stay in the vitreous for 6 months after intravitreal administration.
Dexamethasone implant can lead to retinal nerve fiber layer and optic nerve damage by both increasing intraocular pressure and its direct effect on neural tissue during the effective 6-month period.
|Study Type :||Observational|
|Actual Enrollment :||43 participants|
|Official Title:||The Effect of Dexamethasone Implant on Retinal Nerve Fiber and Optic Disc Morphology in Patients With Diabetic Maculopathy|
|Actual Study Start Date :||February 1, 2018|
|Actual Primary Completion Date :||September 1, 2018|
|Actual Study Completion Date :||January 31, 2019|
- Procedure: intravitreal dexamethasone implant application
Peripapillary RNFL thickness measurements and colored fundus photographs were compared before and 6 months after intravitreal DEX implant injection. The cup-to-disc ratios of fundus photographs were calculated using the Image-J program.Other Name: The Effect of Dexamethasone Implant on Retinal Nerve Fiber and Optic Disc in Diabetic maculopathy.
- Peripapillary RNFL thickness measurements [ Time Frame: six month ]micrometer
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03927118
|Zonguldak Bülent Ecevit Üniversitesi.|
|Zonguldak, Kozlu, Turkey, 67600|
|Study Director:||Atilla Alpay, Ass. Prf.||Zonguldak Bulent Ecevit University|